Primary Biliary Cirrhosis
Pipeline by Development Stage
Drug Modality Breakdown
Gastroenterology is a $7.3B market characterized by mature, blockbuster-driven portfolios with near-term patent cliff risks.
Key Trends
- AbbVie dominance with 43% of top-10 product spending (LINZESS, CREON, RINVOQ)
- Guanylate cyclase activators and JAK inhibitors driving innovation in constipation and IBD
- Multiple patent expirations 2026–2030 creating biosimilar and generic erosion headwinds
Career Verdict
Gastroenterology offers stable, well-compensated roles but limited growth upside; best for risk-averse professionals seeking established markets over innovation-driven career trajectories.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | LINZESS (linaclotide) | AbbVie | $1.8B | 25% | Peak | Stable | 7.7yr |
| 2 | CREON (pancrelipase) | AbbVie | $1.5B | 21% | LOE Approaching | Declining | |
| 3 | XIFAXAN (rifaximin) | Bausch Health | $1.1B | 15% | LOE Approaching | Declining | |
| 4 | RINVOQ (upadacitinib) | AbbVie | $976M | 13% | Peak | Growing | 11.8yr |
| 5 | XELJANZ XR (tofacitinib) | Pfizer | $586M | 8% | Peak | Stable | 8.3yr |
Drug Class Breakdown
mature portfolio anchor
well-established class
facing biosimilar competition
growing IBD adoption
commoditized
Career Outlook
StableGastroenterology is a stable, mature market anchored by blockbusters with long patent runways (LINZESS to 2034, RINVOQ to 2038) but faces near-term erosion (XELJANZ 2026). Employment growth is modest and concentrated in device/diagnostic firms rather than pure-pharma. Best for professionals seeking predictable revenue streams over high-risk innovation bets.
Breaking In
Target roles at Roche, J&J, or diagnostic-adjacent firms to maximize hiring volume; pure pharma gastro entry points at AbbVie/Pfizer are limited and highly competitive.
For Experienced Professionals
Leverage gastro expertise in broader GI/immunology roles (Takeda, Novartis) or transition to medical devices/diagnostics where hiring is 3x higher than pharma.
In-Demand Skills
Best For
Hiring Landscape
Total hiring across the gastro ecosystem is 1,818 jobs, dominated by engineering (434) and commercial roles (269). Roche leads absolute hiring at 377 roles, followed by Johnson & Johnson (323) and GE HealthCare (293), reflecting broad medical device and diagnostic involvement alongside pharma. AbbVie's gastro-specific hiring (78 jobs) is modest relative to its portfolio dominance.
By Department
Manufacturing and commercial roles command premium salaries ($213K and $176K respectively), but total gastro-pharma hiring is concentrated in Roche and J&J, not pure-play GI companies.
Competitive Landscape
16 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 17 trials with date data
Clinical Trials (18)
Total enrollment: 1,302 patients across 18 trials
Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis
Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis
Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone in Primary Biliary Cirrhosis (PBC)
Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody
A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)
Study to Assess Safety & Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodiol.
Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)
An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis
Use of Fenofibrate for Primary Biliary Cirrhosis
Moexipril for Primary Biliary Cirrhosis
Pilot Study of FFP104 Dose Escalation in PBC Subjects
Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Refractory Primary Biliary Cirrhosis
Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis
Related Jobs in Gastroenterology
Medical Science Liaison, Southeast
Sr Scientist, Biomarkers & Translational Inflammation
Senior Scientist, Computational Chemistry
Firmware Engineer - Medical Device
Senior Product Manager, Chat AI & Automation
Software Engineer I/II, Machine Learning
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.